SCHEMBL3246300

SCHEMBL3246300

CC(=O)Nc1ccc2[nH]c(=O)c3[nH]cc(CCC(=O)O)c3c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.47
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 3/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CHEK1 O14757 1/20 0.47
ESR1 P03372 1/20 0.46
MTNR1A P48039 3/20 0.44
MTNR1B P49286 3/20 0.44
KMT2A Q03164 1/20 0.44
ERCC1 P07992 1/20 0.44
DNASE1 P24855 1/20 0.44
FEN1 P39748 1/20 0.44
ERCC4 Q92889 1/20 0.44
CYP1A2 P05177 1/20 0.41
NQO2 P16083 1/20 0.41
CYP2C19 P33261 1/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
TNKS O95271 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4161990 0.89 HPGD (0.38) HPGDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL4165158 0.89 MME (0.42) HPGDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL4166962 0.89 HPGD (0.42) HPGDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL4162539 0.89 MEN1 (0.51) KDM4EALOX15HSD17B10KMT2AMAPT
Hydrochloric Acid SCHEMBL4168323 0.88 HPGD (0.41) HPGDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL4155636 0.87 KDR (0.41) HPGDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL3245758 0.87 BRD4 (0.56) ALDH1A1KMT2ATNKSPARP1PARP15
SCHEMBL4169903 0.86 HTR1A (0.47) HPGDKDM4EALDH1A1HSD17B10KMT2A
SCHEMBL4159606 0.85 SPR (0.46) HPGDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL4172089 0.85 HPGD (0.40) HPGDCYP2C19CA12CA9TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 HPGD 882/4885KDM4E 1970/4885ALDH1A1 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.